CoChat

Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting

Open access
Boulanger-Scemama, E., Querques, G., About, F., Puche, N., Srour, M., Mane, V., Massamba, N., Canoui-Poitrine, F., Souied, E.H. · 2015 · Journal Français d'Ophtalmologie
Cited by 124

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

PURPOSE To analyze adherence to follow-up over 5 years in patients treated with intravitreal ranibizumab for exudative age-related macular degeneration (AMD) in a tertiary health care center. To investigate factors associated with failure to continue follow-up. METHODS Retrospective chart review of all consecutive patients with exudative AMD, who received their first intravitreal ranibizumab injection at the Créteil Intercommunal University Hospital Eye Clinic between October 1, 2006 and March 31, 2007. Patient clinical characteristics at baseline and at the last follow-up visit were recorded. Distance from home to hospital was measured for each patient. A multiple-choice telephone survey was conducted for patients lost to follow-up to determine the main reasons for failure to continue follow-up. RESULTS Two hundred and one patients were included. The rate of loss to follow-up over the 5-year period was 57% (115/201). Fifty-eight patients lost to follow-up completed the questionnaire. The main reasons reported by patients for follow-up discontinuation were long distance from home to hospital (51.7%, 30/58), subjective dissatisfaction with the benefits of intravitreal injections (34.5%, 20/58), and the excessive burden of periodic follow-up visits (24.1%, 14/58). Three factors were significantly associated with follow-up discontinuation: high age at baseline (82.2 vs. 76.5 years, P<0.001), poor best-corrected visual acuity (BCVA) at baseline (42.5 vs. 51.0 letters, P=0.020), and long distance from home to hospital (132 vs. 17.1km, P<0.001). CONCLUSION In this study, adherence to follow-up over 5 years was poor. Age and BCVA at baseline and distance from home to hospital were independently associated with long-term adherence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jfo.2014.11.015

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 124

Metadata

Authors
Boulanger-Scemama, E., Querques, G., About, F., Puche, N., Srour, M., Mane, V., Massamba, N., Canoui-Poitrine, F., & Souied, E. H.
Venue
Journal Français d'Ophtalmologie
Publisher
Elsevier BV
Published
2015-09
Volume
38
Issue
7
Pages
620-627
ISSN
0181-5512 (ISSN-L)
OpenAlex
W2007177737
Cited by
124
References
4
FWCI
6.37
Type
journal article
Language
fr
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. https://app.cochat.ai/papers/10.1016/j.jfo.2014.11.015
The paper
Boulanger-Scemama, E., Querques, G., About, F., Puche, N., Srour, M., Mane, V., Massamba, N., Canoui-Poitrine, F., & Souied, E. H. (2015). Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. Journal Français d'Ophtalmologie. https://doi.org/10.1016/j.jfo.2014.11.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.